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We describe the case of an 86-year-old man presenting with clinical symptoms suggestive of Temporal Arteritis. The evolution
of the case prompted extensive work-up, including temporal artery and kidney biopsy. Based on the clinical and pathological
ﬁndings, a diagnosis of ANCA-negative granulomatous necrotizing vasculitis involving the small-, medium-, and large-size vessels
was made. The patient was treated with prednisone and cyclophosphamide, which was later switched to rituximab. The patient
remained asymptomatic under this regimen and stabilization of his kidney function was achieved.
1.Introduction
Physicians have been continuously trying to ﬁnd a way to
better classify vasculitides in order to facilitate a fast and
accurate diagnosis. Proper diagnosis is extremely important,
as some diseases only require supportive treatment while
others need prompt and aggressive therapy if signiﬁcant
morbidity and mortality is to be avoided. The clinical
picture usually correlates with the size and extent of
vessel involvement. The diﬃculty comes when physicians
encounter complex cases that do not follow any current
classiﬁcation.
Vasculitis of the temporal artery was observed in the
biopsy specimen of a patient with clinical symptoms sug-
gestive of Temporal Arteritis. Progressive renal dysfunction
ensued despite rapid initiation of steroid therapy, prompting
renal biopsy.
2.CaseReport
86-year-old white man was referred to our rheumatology
clinic on July 23rd, 2008. He was complaining of persistent
fatigue, low grade fever, proximal arthralgias, and myalgias,
especially in his hips. He had poor oral intake and weight
loss.APPDtestdoneasoutpatientwasnegative.Hisinability
to eat was attributed to jaw claudication. Patient denied any
vision changes, headaches or scalp tenderness. There was no
skin rash or sicca symptoms.
LaboratoryevaluationrevealedanESRof64mm/H,CRP
167.2mg/L, WBC 12600/cumm, Hb 10.6g/dL, Ht 32.3%,
ferritin 2217ng/mL, albumin 2.6g/dL, BUN 18mg/dL, and
Cr 0.87mg/dL.
A diagnosis of polymyalgia rheumatica and giant cell
arteritis was suspected and treatment with prednisone 60mg
daily was started. Temporal artery biopsy performed in July
of 2008 revealed granulomatous vasculitis with ﬁbrinoid
necrosis. The patient had dramatic improvement of his
symptoms and rapid decline of the inﬂammatory markers.
On August 15th, 3 weeks after initiating steroid therapy, his
ESR decreased to 39mm/h and CRP to 21.7mg/dL. Over the
next three weeks the steroid dose was gradually reduced to
30mg daily. However, he did not tolerate further taper due
to recurrence of polymyalgia-like symptoms.
Despite overall clinical improvement and continuous
treatment with prednisone (20–30mg daily), renal dysfunc-
tion ensued over the three months since the onset of the
patient’s illness. In September, 2008 patient’s BUN rose
to 77mg/dL and Cr to 3.33mg/dL. Urinalysis revealed 2+
proteins,fewRBCs,noRBCcasts,andnoWBC.Atthatpoint
avasculiticprocessinthekidneyswasconsidered,prompting
further workup. The following serologies were negative
or normal: ANCA, C3, C4, CH50, ANA, anti-dsDNA,2 International Journal of Rheumatology
anti-GBM, anticardiolipin antibodies, and cryoglobulins.
Hepatitis panel was negative.
Magnetic Resonance Angiography was negative for renal
artery stenosis. In September, 2008, the kidney biopsy
was performed, showing acute and chronic granulomatous
necrotising vasculitis of medium-sized (renal) arteries and
crescent formation. The immunoﬂuorescence report was
negative for IgG, IgM, IgA, C3, C1, ﬁbrinogen, albumin, or
light chains (Figures 1(a), 1(b),a n d1(c)).
Based on the clinical and pathological ﬁndings, we con-
cluded that our patient had ANCA-negative granulomatous
necrotizing vasculitis involving the small-, medium- and
large-size vessels.
In October, 2008, cyclophosphamide was added to
prednisone. The regimen of cyclophosphamide 50mg daily
alternating with 75mg daily and prednisone 15mg daily
was continued for four months. Of note, higher dose of
cyclophosphamide was not tolerated due to severe leu-
copenia. This regimen achieved stabilization of the renal
function to a creatinine of 2.3–2.5mg/dL and normalization
of the inﬂammatory markers, while no other symptoms
were present. In February, 2009, cyclophosphamide was
discontinued due to the concern for potential side eﬀects
and toxicity of cyclophosphamide. Patient was administered
a course of rituximab, 1000mg 2 doses 2 weeks apart
with intention to prevent the disease ﬂare upon stopping
cyclophosphomide. Patient continued to taper the dose of
prednisonegraduallyanddiscontinueditcompletelyinJune,
2009. As of March of 2010, he feels very well without any
polymyalgiaorcranialsymptoms,resumedhisregulartennis
playing and other activities. His renal function has been
stable with BUN of 35mg/dL and creatinine of 1.64mg/dL.
Inﬂammatory markers, including ESR and CRP are normal.
3. Discussion
Classifying a vasculitis can be a real challenge and most
likely the ﬁnal word in the classiﬁcation has not yet been
said. The current approach using the vessel size (small,
medium, and large) is useful in suggesting clinical features
associated with a particular disease [1]. It is important to
realize that there are unclassiﬁed vasculitic processes when
clinical judgement and case particularities are guiding the
best therapeutic approach. Vessels are very complex and
not enough studied organs as determinants of a vasculitic
pattern. More research is being oriented toward establishing
the basis for this selective vulnerability beyond vessel size.
It has been hypothesized that several factors, including
embryogenesis, age-related changes, immunologic suscepti-
bility, and injury-repair process might be involved in the
etiology and pathogenesis of vasculitis [2].
A patient rarely presents with all of the classic ﬁndings
[3]. Our patient presented with a clinical picture suggestive
of Temporal-Arteritis. Temporal artery biopsy is a simple
tool for diagnosis of vasculitis, but vasculitis of the temporal
artery is not limited to Giant Cell Arteritis. Other systemic
vasculitides (e.g., Polyarteritis nodosa, Wegener’s granulo-
matosis, microscopic polyangiitis, Churg-Strauss Syndrome,
Systemic Lupus Erythematosus) may show inﬂammatory
changes on the temporal artery biopsy [4–8]. There have
been case reports of systemic vasculitis (e.g.,Wegener gran-
ulomatosis), found to have biopsy-proven vasculitis of the
temporal artery [9]. In 2003, Hamidou et al. reported seven
cases of systemic necrotizing vasculitis with histologically




temporal artery biopsy was done in that patient. In our
patient the biopsy of the temporal arteries showed granulo-
mas and ﬁbrinoid necrosis. Fibrinoid necrosis is atypical for
giant cell arteritis and its presence should raise doubts about
such a diagnosis [11].
Our patient’s kidney biopsy was consistent with
pauci-immune ANCA-negative granulomatous necrotizing
glomerulonephritis. The rare ﬁnding of granuloma in the
kidney biopsy, mandated the exclusion of other potential
culprits beside the vasculitic etiology (most commonly
Wegener’s granulomatosis). The diﬀerential diagnosis of
granulomatous renal disease is broad, including tuberculosis
as a classic cause of noncaseating granuloma. Our patient
had no risk factors for tuberculosis, negative PPD test, and
no pulmonary symptoms whatsoever. We excluded also
other potential infectious causes (e.g., fungal infections like
histoplasmosis and cryptococcosis, chronic pyelonephritis,
cat-scratchfever).Therewasnoclinicalorimagisticevidence
of sarcoidosis, either.
Chaveau et al. showed that renal involvement occurs in
75% of the patients with systemic necrotizing small-vessel
vasculitis [12]. The absence or paucity of vascular immune
deposits distinguishes microscopic polyangiitis, Wegener’s
granulomatosis(WG)andChurg-Strausssyndromefromthe
variety of necrotizing vasculitides.
The classic triad of respiratory tract granulomatous
inﬂammation, systemic small-vessel vasculitis and necrotiz-
ing glomerulonephritis suggests the diagnosis of WG, but
a lot of patients do not present with the classic ﬁndings.
Antineutrophilic cytoplasmic antibody testing (ANCA) is
a very important diagnostic aid, with 70% of the WG’s
having antibodies towards proteinase 3(PR3-ANCA), 20%
against myeloperoxidase, while 10% may be ANCA negative.
Approximately 80% of the patients with WG will have
glomerulonephritis. The glomerulonephritis is characterized
by focal necrosis, crescent formation, and the absence
or paucity of immunoglobulin deposits. A similar pauci-
immune,crescentic,necrotizing glomerulonephritis isfound
in patients with microscopic polyangiitis and Churg-Strauss
Syndrome. The latter is characterized by a triad of asthma,
eosinophilia and necrotizing granulomatous vasculitis. P-
ANCA(or anti-MPO) is positive in 35%–75% of patients
and up to 10% can have a positive C-ANCA. Microscopic
polyangiitis is diﬀerentiated by the absence of asthma
and development of rapidly progressive glomerulonephritis
(RPGN) without granulomata. Over 80% of patients have
ANCA, mostly perinuclear type.
Our case though, does not ﬁt into any of the classic
granulomatous necrotizing vasculitis.International Journal of Rheumatology 3
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Figure 1: (a) Crescent formation. (b) Granuloma. (c) Vasculitis in medium-sized renal artery.
When facing a systemic vasculitis it is extremely impor-
tant to make an accurate diagnosis. As of yet we have no
diagnostic criteria to diﬀerentiate vasculitis. A clinician has
to take into consideration both the clinical manifestations
and the histological ﬁndings, in his endeavors to understand
these rare and devastating conditions [13].
Tissue-sampling is an invaluable tool in establishing
the correct diagnosis. Aggressive, early, and appropriate
treatment minimizes disease-related mortality and irre-
versible damage. Whereas steroid treatment is usually suf-
ﬁcient for Giant Cell Arteritis, renal involvement in the
form of glomerulonephritis, traditionally requires addition
of immunopsupressive drugs. Before the institution of
immunosuppressive therapy, the mortality rate of patients
with systemic vasculitis (such as WG or polyarteritis nodosa)
was 75% at 5 months. When cyclophosphamide was admin-
istered along with corticosteroids, the 5-year mortality rate
lowered to 12% [3]. The risks and beneﬁts of aggressive
immunosuppression must be assessed in each patient and
treatment established accordingly.
Our case does not fall into any classiﬁable vasculitic
proﬁle. To our best knowledge, this is the only reported
case of ANCA-negative systemic granulomatous necrotizing
vasculitisinvolvingsmall-,medium-,andlarge-sizevesselsin
a patient facing the diagnosis of a systemic, yet unclassiﬁed
vasculitis.
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